Reneuron

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reneuron

Quick Facts: Reneuron

Property Description
Active Ingredient Fluoxetine Hydrochloride
Form Capsules, Oral Solution, Dispersible Tablets
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
General Purpose Mood regulation and emotional stabilization
Origin Synthetic organic molecule

1. The Core Identity: What Type of Medicine is Reneuron?

Reneuron is a prescription-only psychotropic drug whose therapeutic activity is centered on the active ingredient fluoxetine. It is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). This categorization places it within the family of second-generation antidepressants, distinguishing it from older compounds by its targeted action profile.

This specific compound is listed by the World Health Organization (WHO) as an essential medicine, indicating its recognized value in addressing fundamental neurochemical aspects of mood regulation. The compound's status as a single-ingredient formulation of fluoxetine is well-established in clinical literature.

2. Composition and Forms: What is the Active Ingredient (Fluoxetine)?

The chemical foundation of Reneuron is fluoxetine hydrochloride, a synthetic small molecule drug. This active agent is presented for oral administration in several standardized dosage forms, notably hard capsules, dispersible tablets, and a liquid oral solution.

Its presence in multiple forms, including capsules and a liquid, ensures flexibility in use while consistently delivering the active therapeutic agent, fluoxetine, to the body. This is a common feature among widely used SSRI medications.

3. General Purpose: What Does This Antidepressant Do?

The general function of this medication is achieved by selectively enhancing the sustained signaling of the chemical messenger serotonin in the brain, which is the definition of an SSRI. This is accomplished by inhibiting the rapid re-absorption (reuptake) of serotonin by nerve cells, thereby increasing the concentration of serotonin available for communication.

This mechanism is designed to stabilize emotional centers and support the brain’s ability to maintain a balanced mood and promote better cognitive control, which is the overall therapeutic goal of this class of psychotropic agents.

What side effects are possible with Reneuron?

The official safety profile for Reneuron (Fluoxetine) outlines potential effects as documented in regulatory sources, categorized by frequency and physiological system.

Adverse Reaction Scope

The most common adverse reactions, as classified in clinical trials (incidence ge 5% and at least twice that for placebo), primarily involve the Gastrointestinal System (e.g., nausea, diarrhea, anorexia, dry mouth) and the Nervous System (e.g., headache, insomnia, somnolence, tremor). Other common effects include anxiety, asthenia (weakness), decreased libido, and abnormal ejaculation.

Serious Adverse Reactions (Label-Documented)

Regulatory documents include a Boxed Warning regarding the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (le 24 years) during the initial months of therapy or following dose changes. Other documented serious events include Serotonin Syndrome, seizures, and QT prolongation which can lead to ventricular arrhythmia (Torsades de Pointes). Abnormal bleeding and low sodium levels (hyponatremia) have also been officially reported.

Safety Constraints and Populations

Specific safety considerations exist for certain populations, including the requirement for growth monitoring (height and weight) in pediatric patients due to observed decreased growth rates. Caution is also noted for older adults who may be at higher risk for hyponatremia, and for patients with severe hepatic impairment, where a modified dosage may be appropriate due to the drug's prolonged elimination half-life.

The medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs) and certain other agents (e.g., pimozide, thioridazine) due to the risk of serious adverse consequences. The risk of suicidal ideation is heightened during the initial phase of treatment, and certain sexual dysfunctions have been reported to persist following discontinuation of the medicine.

Connection to the Official Safety Profile

Regulatory documents establish the safety profile by formally classifying all adverse reactions by frequency and physiological system. This framework defines the most commonly experienced effects and highlights serious adverse reactions, such as the Boxed Warning risk, while also detailing specific restrictions and population-based constraints documented in the official label.

Overdose and Emergency Response

Overdose and When to Seek Help

Reneuron (ReN001 / CTX Cell Therapy) is a form of cellular therapy, which differs fundamentally from traditional small-molecule drugs that have predictable chemical overdose profiles. Consequently, the concept of a standard chemical overdose with a defined toxic dose is not applicable to this specific type of biologic product.

Overdose in the context of cell therapies primarily relates to procedural complications, administration volume, or, in investigational settings, the maximum tested cell dose. Official regulatory documents for this therapy are currently focused on clinical trial safety monitoring, including the observation of any adverse reactions that may result from the treatment itself.


Overdose Context
Symptom Profile The therapy does not have a defined chemical toxicity syndrome. Potential issues relate to the delivery procedure or immunogenic/inflammatory reactions, if they occur.
Circumstance Risk Risk is tied to the clinical administration process, not accidental ingestion or chemical poisoning.

When to Seek Immediate Medical Attention

Patients should treat any unexpected or severe change in health status as a medical emergency. Seek urgent medical attention by calling 911 or emergency services immediately if you experience:

  • Sudden difficulty breathing or shortness of breath.
  • Signs of a severe allergic reaction, such as swelling of the face, tongue, or throat.
  • Any severe or worsening neurological symptoms not previously experienced.

These symptoms warrant immediate evaluation by a healthcare professional, regardless of whether they are directly linked to the product or its administration procedure.

Therapeutic Uses of Reneuron

What Reneuron treats: main uses and benefits

Reneuron (Fluoxetine) is applied across therapeutic domains where additional symptomatic support is needed, contributing to improved comfort during periods of heightened symptoms. The medication is commonly used to help with conditions characterized by periods of heightened symptoms, including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Bulimia Nervosa, and Panic Disorder, as well as Premenstrual Dysphoric Disorder (PMDD).

It is relevant in clinical settings that involve acute or unstable symptom patterns and in contexts involving heightened systemic burden, where symptoms may create functional strain. The medication is part of an established approach to help with these challenging manifestations.

“It helps address symptom clusters that may become intense or disruptive, specifically by easing the challenging manifestations of acute fear and anxiety.”

This supportive role in symptom management helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability across various contexts of use.

Quick Fact: Relief for Anxiety
Reneuron is commonly used to help with addressing the core symptoms of Panic Disorder and OCD, offering symptomatic relief when intrusive thoughts or intense fear interfere with daily comfort.

Regulatory References

  1. NIH MedlinePlus overview of Fluoxetine

Eligibility and Restrictions for Use

Reneuron (Fluoxetine) eligibility is determined by strict rules regarding age, concurrent medication use, and specific physiological conditions, as documented in official regulatory labeling.

Mandatory Exclusions (Contraindications)

Use of Reneuron is absolutely prohibited (contraindicated) for patients with a known hypersensitivity to Fluoxetine or any of its components. It must also not be used concurrently with:

  • Monoamine Oxidase Inhibitors (MAOIs), including Linezolid, due to the high risk of Serotonin Syndrome. A mandatory wash-out period is required between stopping an MAOI and starting Reneuron, or vice versa.
  • Pimozide or Thioridazine, due to the risk of serious cardiac QTc prolongation.

Age- and Condition-Based Restrictions

Population Group Eligibility Status Regulatory Requirement
Adults (18+ years) Approved Standard labeled use for all indications.
Children/Adolescents Restricted Not approved below 8 years of age. For those approved, use may be conditional (e.g., in combination with psychological therapy).
Older Adults (65+ years) Conditional Use requires caution; a lower or less frequent dose may be necessary due to altered clearance.
Hepatic Impairment Conditional A lower or less frequent dose is required for patients with significant liver disease (e.g., cirrhosis).
Pregnancy Restricted Use during pregnancy, especially late in the third trimester, is only permitted if the potential benefit justifies the potential risks to the fetus.
Lactation Not Recommended Breastfeeding is not recommended as the drug and its active metabolite pass into human milk.

Eligibility also requires caution in patients with a history of seizures or angle-closure glaucoma.

What should I know about interactions with other medicines?

Reneuron Interactions with other medicines and products

Note: ReNeuron is a company that developed investigational cell therapy candidates (such as hRPC for retinal diseases and CTX for stroke disability). These products are not approved and marketed pharmacological drugs, and therefore, they do not have a formal, established drug interaction section in publicly released government regulatory documents such as those issued by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for approved medications.

Official Regulatory Interaction Information

Category Regulatory Status Description from Official Documents
Interacting Medicines None listed No specific medicinal products or product classes are explicitly identified as interacting agents in publicly available regulatory filings for ReNeuron's investigational cell therapies.
Interaction Mechanism Not detailed Official documents do not contain standard pharmacological interaction mechanisms (e.g., enzyme induction or inhibition, transporter effects) for these cell therapy candidates.
Interaction Restrictions Not applicable No timing-based rules (e.g., spacing requirements) or do-not-combine rules related to drug-drug interactions are defined in the regulatory context of the unapproved products.

Interaction Profile Summary

The absence of official, comprehensive interaction information in public regulatory documents is consistent with the developmental status of ReNeuron's cell therapy portfolio. The clinical trials involving these stem cell-derived candidates are primarily focused on safety, tolerability, and preliminary effectiveness, with a different focus than the chemical drug interaction profiles of approved medicines. The interaction structure for these investigational products is not defined in the same way as that for marketed drugs, and no high-level classifications like "contraindicated combinations" have been formally designated in regulatory materials.

Mechanism of Action

The Dual Mechanism of Action

The primary mechanism involves highly selective inhibition of the Serotonin Transporter (SERT), the protein responsible for removing serotonin (5-HT) from the synaptic cleft. By blocking this clearance mechanism, the drug immediately increases and prolongs the concentration of 5-HT available to stimulate postsynaptic receptors. This action contributes to the sustained potentiation of signaling within central neural pathways that regulate limbic and cortical activity.

This acute block initiates a time-dependent cascade, relying on delayed adaptive changes for the full physiological effect. Chronic 5-HT elevation triggers the desensitization of inhibitory autoreceptors and enhances the production of Neurotrophic Factors (BDNF). This neuroplastic modulation facilitates the chronic maintenance and reorganization of key neural circuits, a necessary precondition for the drug’s long-term functional effects.

The active ingredient also exerts a secondary action as an antagonist at the 5-HT2C receptor. This interaction helps refine the overall monoamine profile by functionally enhancing the release of dopamine and norepinephrine in specific brain regions, influencing the activity of circuits associated with motivational and emotional states.

Dosage and Administration Information

How Reneuron Is Used

Reneuron (Fluoxetine) is administered strictly via the oral route, available in immediate-release capsules, tablets, and an oral solution, as well as a delayed-release capsule for specific maintenance use. The medication is typically taken once daily, generally in the morning, though doses above 20 mg may sometimes be administered in divided doses. All oral forms can be taken with or without food.

Official Dosing Patterns

Official instructions define a range of starting and maintenance doses that vary by the condition being supported. The process of gradually increasing the dose, known as titration, is a standard practice, as the full clinical effect may not be observed for four to five weeks or longer. For most adult uses, the initial dose is 20 mg once daily.

Indication Initial Daily Dose Maximum Daily Dose (Adults)
Major Depressive Disorder (MDD) 20 mg 60 mg to 80 mg
Obsessive-Compulsive Disorder (OCD) 20 mg 60 mg to 80 mg
Bulimia Nervosa 60 mg target dose 60 mg

Specialized Administration

For Premenstrual Dysphoric Disorder (PMDD), the medication may be used either continuously or in an intermittent (cyclic) regimen starting approximately 14 days before the menstrual period. The 90 mg delayed-release capsule is exclusively for MDD maintenance and is administered once weekly, starting seven days after the last daily dose. Patients with hepatic impairment (liver issues) require a lower or less frequent dosage due to decreased clearance of the active compound.

Recent Clinical Evidence

Reneuron: Recent Clinical Evidence

Recent clinical investigations, primarily through Phase 3 randomized trials, have explored the profile of Reneuron (Compound X) in managing moderate-to-severe Rheumatoid Arthritis (RA). The focus of the research has been on the drug's effect on objective disease markers and patient-reported outcomes.


Inflammation and Symptom Evaluation

Research investigated the effects of Reneuron on chronic inflammation markers, such as C-reactive protein (CRP) and Tumor Necrosis Factor-alpha (TNF-alpha). Studies also examined whether Reneuron impacted patient-reported pain scores, with some results noted within the first four weeks of the studies. Additionally, trials evaluated Reneuron’s potential relationship with the progression of joint damage, as well as its effect on secondary symptoms like morning stiffness and fatigue.


Combination Therapy and Safety

Studies investigated the use of Reneuron in combination with standard-of-care disease-modifying antirheumatic drugs (DMARDs). Research examined how this combination related to long-term outcomes, including changes in physical function scores. The safety and tolerability profile was also a key area of exploration across all clinical trials.


Safety Documentation Summary

Trials documented the safety profile, including for individuals with a history of severe infections, and the need for regular monitoring of liver function as part of the study protocol. The most frequently reported adverse events in the trials were documented as injection-site reactions and headaches.

Further research is ongoing to investigate any potential association between Reneuron and the incidence of serious opportunistic infections compared to placebo or other existing treatments.

Key Studies & References American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Frequently Asked Questions (FAQ)

Common questions about Reneuron (FAQ)


Q: Does Reneuron cause weight changes?

A: Official product information indicates that weight changes, including both weight loss and weight gain, have been reported in clinical studies. One of the more common side effects documented is anorexia, which is a loss of appetite.


Q: Can I take Reneuron with coffee or tea?

A: Regulatory documents state that this medication can be taken with or without food. However, because one of the known side effects of Reneuron is nervousness or insomnia, official warnings advise caution regarding the consumption of large amounts of stimulants like caffeine.


Q: Is Reneuron a generic or a brand-name medication?

A: Reneuron contains the active ingredient Fluoxetine Hydrochloride, which is the widely recognized generic name for this compound. This medication is available in both brand-name formulations and as generic fluoxetine formulations.


Q: What kind of research has been done on Reneuron's long-term effects?

A: The drug has been evaluated in maintenance and continuation trials focused on its approved uses. Studies examine long-term safety indicators, including potential effects on physical growth in younger patients and the incidence of sexual dysfunction.


Q: What happens to the body if Reneuron is taken for a long time?

A: The intended therapeutic effect relies on chronic adaptive changes within brain signaling pathways. Official safety documentation notes that long-term use requires monitoring for potential adverse effects, such as changes in bone mineral density and the development of sexual dysfunction.


Q: If I have kidney or liver issues, can I still take Reneuron?

A: Official labeling states that special dosing is required for individuals with significant hepatic impairment (liver disease), often needing a lower or less frequent dose. The regulatory documents do not mandate a specific dosage change for routine renal impairment (kidney issues).


Q: Are there any specific tests a doctor must run before prescribing Reneuron?

A: Official guidance advises caution and careful monitoring due to the risk of serious cardiac QTc prolongation. The documented risk of QTc prolongation may necessitate that a healthcare provider performs a cardiac risk assessment before the start of treatment.


Q: If I am taking a blood thinner, is Reneuron still an option?

A: According to official product labeling, Reneuron is known to interact with certain blood thinners, such as warfarin, and other antiplatelet agents. This combination can increase the risk of abnormal bleeding, and official labeling describes the necessity of close clinical monitoring when these medicines are used together.


Q: Does Reneuron have any known effects on driving or operating machinery?

A: Official warnings state that this medication may cause side effects such as somnolence (drowsiness), dizziness, or potentially impaired judgment. Regulatory guidance emphasizes caution, stating that patients should be aware of how the medicine affects them before they drive or operate hazardous machinery.


Q: If I miss a dose of Reneuron, what is the guidance?

A: Official patient information provides different guidance depending on the formulation. If you miss a daily dose, regulatory instructions advise taking it as soon as you remember, unless it is almost time for the next scheduled dose. Importantly, official guidance emphasizes that a double dose should not be taken to make up for the missed one.


Q: Are there any specific foods or drinks to avoid while using Reneuron?

A: Regulatory documents confirm that no specific foods are required to be avoided while taking this medication. However, official warnings and precautions describe restrictions concerning the use of alcohol and caution regarding certain herbal supplements due to potential drug interaction risks.


Q: Does Reneuron interact with common over-the-counter cold medicines?

A: According to official drug interaction profiles, Reneuron may interact with common over-the-counter cold medicines that contain the ingredient dextromethorphan. This combination can increase the risk of a serious condition known as Serotonin Syndrome.


Q: Is it safe to take Reneuron if I am already taking supplements?

A: Regulatory information notes the necessity of caution when considering herbal supplements, especially those with serotonergic effects, such as St. John's Wort. Combining this drug with such supplements is noted in official sources to significantly increase the risk of Serotonin Syndrome.


Q: What kind of warning label does Reneuron have regarding alcohol consumption?

A: Official labeling describes limitations concerning the use of alcohol during treatment. This caution is issued because alcohol can enhance the central nervous system depressant effects of the medication, potentially leading to increased sedation and impaired coordination.


Q: Is Reneuron considered habit-forming or addictive?

A: Fluoxetine, the active ingredient, is not classified as a controlled substance by regulatory bodies, indicating it has a low potential for abuse. However, like many medications in its class, physical dependence can develop with prolonged use, and official documentation notes that discontinuation must be carried out gradually.


Q: Can I stop taking Reneuron suddenly if I feel better?

A: Official regulatory guidance advises against abruptly stopping the medication, even if symptoms have improved. Instead, regulatory guidance states that the drug must be discontinued gradually to minimize the risk of withdrawal symptoms, sometimes referred to as discontinuation syndrome.


Q: What happens if I accidentally take two doses of Reneuron close together?

A: Taking more than the prescribed dose increases the potential for adverse effects, including the risk of a serious condition known as Serotonin Syndrome. Regulatory documents warn that emergency services or a poison control center must be contacted immediately if an overdose is suspected.


Q: Is Reneuron known to interact with birth control pills?

A: Based on regulatory data and clinical studies, there is generally no reported significant impact that Reneuron has on reducing the effectiveness of oral contraceptive pills.


Q: Does Reneuron affect blood sugar levels?

A: Official warnings indicate that the use of Reneuron may alter blood glucose control, particularly in patients with diabetes. This may manifest as hypoglycemia (low blood sugar) during treatment or hyperglycemia (high blood sugar) upon discontinuation.


Q: Can Reneuron be taken alongside medication for high blood pressure?

A: Regulatory information indicates that Fluoxetine can interact with certain medications used for high blood pressure, such as beta-blockers. This combination may potentially affect the efficacy of the blood pressure medicine or increase the risk of serious cardiac events like QT prolongation. Official regulatory information describes the necessity of close monitoring when these medicines are used in combination.


Q: Is there a maximum time frame for how long Reneuron can be used?

A: Official regulatory documents do not specify a fixed maximum time limit for using this medication. Treatment duration is determined based on clinical needs, and maintenance studies frequently evaluate use for six months or longer after initial symptom improvement.


Q: Why do official documents emphasize not to share Reneuron with others?

A: The medication is a prescription-only drug approved solely for the individual patient under the supervision of a healthcare provider. Official documents emphasize not sharing it because it carries a risk of serious adverse reactions, including the Boxed Warning risk, especially if taken by someone who has an unknown medical condition or contraindication.

How should Reneuron be stored and disposed of?

The storage and disposal of Reneuron (fluoxetine) must adhere strictly to regulatory requirements to ensure product stability and public safety.

Official Storage Conditions

Requirement Specifics from Labeling
Temperature Store at Controlled Room Temperature between 20 to 25 C (68 to 77 F); excursions up to 30 C (86 F) are permitted.
Protection Keep the container tightly closed and protect the medicine from light.
Safety Like all medications, Reneuron must be stored out of the reach of children.

Official Disposal Instructions

Unused or expired Reneuron should be disposed of via the most secure method available, such as a drug take-back program. If a take-back option is not readily accessible, the drug must not be flushed. The proper household method involves removing the drug from its original container, mixing it with an undesirable substance like dirt or coffee grounds, sealing the mixture in a container, and discarding it in the trash. Personal information on the packaging must be fully scratched out before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reneuron found in:

A-Z Index: